Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib plus temozolomide in IDH-mutant glioma (Japan)
jRCT2031240734Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of vorasidenib in glioma, IDH2-mutant glioma, astrocytoma and 1 more (2 cohorts), sponsored by Servier. Primary endpoints: Dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and 3 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
gliomaIDH2-mutant gliomaastrocytomaoligodendroglioma IDH-mutant
Beyond the preview
Go deeper on jRCT2031240734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240734.